Abstract: The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID No1, a peptide B having at least the amino acid sequence of SEQ ID No45, a peptide C having at least the amino acid sequence of SEQ ID No127, a peptide D having at least the amino acid sequence of SEQ. ID No174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.

Abstract: An adhesive composition made by reacting a soy protein with at least one compound under conditions sufficient for introducing additional phenolic hydroxyl functional groups, amine functional groups, and/or thiol functional groups into the soy protein structure.

Abstract: The invention relates to the field of drug delivery, in particular, to compounds and methods for the chemical modification of a proteinaceous channel to be used in pharmaceutical delivery vehicles for controlled and/or localized release of therapeutic molecules (e.g., small molecules, peptides, proteins or other macromolecules). Provided are pH- and/or light-responsive compounds capable of controlling the channel activity of a mechanosensitive channel, such as the MscL channel protein of E. coli, or a functional equivalent thereof, and use of these compounds to convert a mechanosensitive channel protein into a pH- and/or light-responsive channel. Also provided are drug delivery vehicles comprising a pH- and/or light-responsive channel protein.

Abstract: PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating diseases states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.

Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example insulin and Peptide T or analog thereof.

Abstract: The present invention is directed to an ? thio-containing compound that is capable of inhibiting the enzyme, membrane aminopeptidase P (mAPP or APP), whose natural substrate is bradykinin. The compound is useful as a pharmaceutical agent because by inhibiting bradykinin degradation, the compound allows bradykinin to exert its beneficial effects on the cardiovascular system, to improve renal function, and to improve glucose tolerance and insulin-sensitivity. The present invention is also directed to a pharmaceutical composition comprising the mAPP inhibitor of the present invention and a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method of inhibiting bradykinin degradation in a mammalian patient, preferably human, in need of treatment comprising administering to the patient a therapeutically effective amount of an ? thio-containing compound of the present invention.

Abstract: Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.

Abstract: This invention relates to: a labeled amino acid that can be introduced into a protein with the aid of a protein synthesis system; a functional protein having functions derived from a label compound; a labeled amino acid comprising an aromatic ring bound to an amino acid side chain and a label compound bound thereto via the aromatic ring; a functional protein to which the labeled amino acid has been introduced; and a novel method for effectively obtaining a labeled amino acid-tRNA complex.

Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.

Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

Abstract: The present invention provides novel polypeptides comprising heat shock protein 20(HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.

Abstract: The compounds of the present invention are represented by the chemical structure found in Formula I: or a pharmaceutically acceptable salt thereof, with X, R0, R1, and R2 defined herein.

Abstract: Peptide derivatives useful as inhibitors of activity of thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) are of formula Ia: wherein: R1 is an optionally substituted 4-, 5- or 6-membered heterocyclic ring having one or more heteroatoms, in which at least one carbon atom of the ring is substituted with O or S; X1 is —CO— or —CS— or —CH2CO— or CH(R4) wherein R4 is H or optionally substituted alkyl or —COOH or —COOR11 wherein R11 is optionally substituted alkyl; X2 and X3 (which may be the same or different) are —CO— or —CS—; Z is —CH2— or —S— or —O— or —NH—; Q is O or S; R2 is H or optionally substituted alkyl or an optionally substituted carbocyclic ring; R3 is H or optionally substituted alkyl or an optionally substituted mono- or polycyclic ring, optionally having one or more heteroatoms in the ring(s) and optionally being a fused ring; or R2 and R3 together form an optionally substituted mono- or polycyclic ring optionally having one or more heteroatoms in the ring(s) and optionally being a

Abstract: Novel insulin precursors and insulin precursor analogs comprising a connecting peptide (mini C-peptide) of preferably up to 15 amino acid residues and comprising at least one Gly are provided. The precursors can be converted into human insulin or a human insulin analog. The precursors will typically have a distance between B27 (atom CG2) and A1 (atom CA) of less than 5 ?.

Abstract: Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. Peptides which comprise an amino acid sequence of the formula: X-Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.

Abstract: The invention generally relates compositions and methods for the treatment of patients with melanoma and other malignant cancers. The compositions of the present invention are novel peptide sequences that inhibit seprase-mediated cell migration. Said sequences may also be used for diagnostics and library screening protocols.

Abstract: The present invention relates to methods for prevention and treatment of bone-related disorders and calcium homeostasis related syndromes using a GLP-2 molecule or GLP-2 activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.

Abstract: The present invention relates to a class of anti-microbial peptides, called Phyllosepti ns, isolated from Phyllomedusa hypochondrialis. The invention also relates to therapeutic and agricultural compositions comprising one or more Phylloseptins. Methods of treating infections of various mammalian organs such as the skin and methods of treating plant infections are also included in the invention.

Abstract: Analogues of the amino acid sequence KAPREKY and their use in screening for compounds which interacts with Fc?RI?.

Abstract: The present invention relates to methods and reagents for [18F]-fluorination, particularly of peptides. The resultant 18F-labelled compounds are useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET). Thus, a compound of formula 18F-(Linker)-SH, such as a compound of formula (IV), (V), or (VI): 18F—(CH2CH2O)n—(CH2)m—SH ??(IV) 18F—(CH2)p—SH ??(V) may be reacted with an activated peptide as a means for 18F-labelling.